Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/12/22
Aadi Bioscience Announces Collaborations with Next Generation Sequencing LeadersGlobeNewsWire • 05/09/22
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid ServicesGlobeNewsWire • 05/04/22
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022GlobeNewsWire • 04/28/22
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)GlobeNewsWire • 04/08/22
Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 GenesGlobeNewsWire • 03/31/22
Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/17/22
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen's 42nd Annual Health Care ConferenceGlobeNewsWire • 03/01/22
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComaGlobeNewsWire • 02/23/22
Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual ConferenceGlobeNewsWire • 01/04/22
Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form CancerBenzinga • 11/23/21
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)GlobeNewsWire • 11/23/21
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)GlobeNewsWire • 11/15/21
Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)GlobeNewsWire • 11/13/21
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/10/21
Aadi Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/21
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical OncologyGlobeNewsWire • 10/22/21
Aadi Bioscience to Participate in H.C. Wainwright's 2nd Annual Precision Oncology Conference 2021GlobeNewsWire • 10/19/21
Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/06/21